ASTRAZENECA has announced
the US$1.15 billion acquisition of
Pearl Therapeutics, a company
which specialises in chronic
obstructive pulmonary disease.
The deal gives A-Z access to
Pearl’s late-stage COPD therapy
PT003 and its “inhaler and
formulation technology”.The above article was sent to subscribers in Pharmacy Daily's issue from 12 Jun 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Jun 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.